Overview
PASG market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
No longer tradingThis symbol is retired in our registry: it no longer trades, so it has no live decision and cannot be traded here.
- Last Close
- $3.96
- Last Trading Day
- 2026-11-16
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
PASG price chart · 1M
- O
- 3.92
- H
- 3.96
- L
- 3.92
- C
- 3.96
- Vol
- 200.00
Daily history from May 27, 2025
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- stale
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $3.92
- Previous Close
- $4.22
- Day High
- $3.96
- Day Low
- $3.92
- 52 Week High
- $19.81
- 52 Week Low
- $3.33
- 7 Day Return
- +4.62%
- 30 Day Return
- +8.20%
- 90 Day Return
- -14.47%
- 1 Year Return
- -55.38%
- Daily Notional Volume
- $792 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.52 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.29 – $20.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $13.7M · P/B 1.96.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
4 captured